Headlines about Pulmatrix (NASDAQ:PULM) have trended somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Pulmatrix earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.6295493189368 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Pulmatrix (NASDAQ:PULM) opened at 2.00 on Thursday. Pulmatrix has a 1-year low of $0.50 and a 1-year high of $6.98. The stock has a 50 day moving average price of $1.89 and a 200-day moving average price of $2.60. The company’s market cap is $40.25 million.
Pulmatrix (NASDAQ:PULM) last issued its earnings results on Friday, August 4th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. Pulmatrix had a negative return on equity of 152.56% and a negative net margin of 3,328.91%. Equities research analysts forecast that Pulmatrix will post ($4.13) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Pulmatrix (PULM) Stock Price” was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://transcriptdaily.com/2017/09/14/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-pulmatrix-pulm-stock-price.html.
Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.
Receive News & Ratings for Pulmatrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.